Taiwan · Delayed Price · Currency is TWD Syngen Biotech Statistics
Total Valuation
Syngen Biotech has a market cap or net worth of TWD 2.60 billion. The enterprise value is 2.45 billion.
| Market Cap | 2.60B |
| Enterprise Value | 2.45B |
Important Dates
The next estimated earnings date is Monday, May 11, 2026.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | Jun 26, 2025 |
Share Statistics
Syngen Biotech has 27.10 million shares outstanding. The number of shares has increased by 2.61% in one year.
| Current Share Class | 27.10M |
| Shares Outstanding | 27.10M |
| Shares Change (YoY) | +2.61% |
| Shares Change (QoQ) | +22.92% |
| Owned by Insiders (%) | 7.00% |
| Owned by Institutions (%) | 3.25% |
| Float | 10.96M |
Valuation Ratios
The trailing PE ratio is 10.96.
| PE Ratio | 10.96 |
| Forward PE | n/a |
| PS Ratio | 1.26 |
| PB Ratio | 1.15 |
| P/TBV Ratio | 1.16 |
| P/FCF Ratio | 8.02 |
| P/OCF Ratio | 6.95 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.84, with an EV/FCF ratio of 7.55.
| EV / Earnings | 10.04 |
| EV / Sales | 1.18 |
| EV / EBITDA | 5.84 |
| EV / EBIT | 8.14 |
| EV / FCF | 7.55 |
Financial Position
The company has a current ratio of 1.84, with a Debt / Equity ratio of 0.07.
| Current Ratio | 1.84 |
| Quick Ratio | 1.10 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.40 |
| Debt / FCF | 0.51 |
| Interest Coverage | 58.61 |
Financial Efficiency
Return on equity (ROE) is 11.00% and return on invested capital (ROIC) is 10.80%.
| Return on Equity (ROE) | 11.00% |
| Return on Assets (ROA) | 6.04% |
| Return on Invested Capital (ROIC) | 10.80% |
| Return on Capital Employed (ROCE) | 12.21% |
| Weighted Average Cost of Capital (WACC) | 5.04% |
| Revenue Per Employee | 8.37M |
| Profits Per Employee | 987,170 |
| Employee Count | 247 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 3.55 |
Taxes
In the past 12 months, Syngen Biotech has paid 57.20 million in taxes.
| Income Tax | 57.20M |
| Effective Tax Rate | 19.00% |
Stock Price Statistics
The stock price has decreased by -20.41% in the last 52 weeks. The beta is 0.17, so Syngen Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | -20.41% |
| 50-Day Moving Average | 109.42 |
| 200-Day Moving Average | 120.35 |
| Relative Strength Index (RSI) | 19.33 |
| Average Volume (20 Days) | 27,637 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Syngen Biotech had revenue of TWD 2.07 billion and earned 243.83 million in profits. Earnings per share was 8.76.
| Revenue | 2.07B |
| Gross Profit | 687.05M |
| Operating Income | 296.08M |
| Pretax Income | 301.03M |
| Net Income | 243.83M |
| EBITDA | 398.79M |
| EBIT | 296.08M |
| Earnings Per Share (EPS) | 8.76 |
Balance Sheet
The company has 319.87 million in cash and 165.63 million in debt, with a net cash position of 154.24 million or 5.69 per share.
| Cash & Cash Equivalents | 319.87M |
| Total Debt | 165.63M |
| Net Cash | 154.24M |
| Net Cash Per Share | 5.69 |
| Equity (Book Value) | 2.27B |
| Book Value Per Share | 68.05 |
| Working Capital | 537.53M |
Cash Flow
In the last 12 months, operating cash flow was 374.32 million and capital expenditures -49.98 million, giving a free cash flow of 324.34 million.
| Operating Cash Flow | 374.32M |
| Capital Expenditures | -49.98M |
| Depreciation & Amortization | 102.71M |
| Net Borrowing | -183.40M |
| Free Cash Flow | 324.34M |
| FCF Per Share | 11.97 |
Margins
Gross margin is 33.24%, with operating and profit margins of 14.32% and 11.80%.
| Gross Margin | 33.24% |
| Operating Margin | 14.32% |
| Pretax Margin | 14.56% |
| Profit Margin | 11.80% |
| EBITDA Margin | 19.29% |
| EBIT Margin | 14.32% |
| FCF Margin | 15.69% |
Dividends & Yields
This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 5.19%.
| Dividend Per Share | 5.00 |
| Dividend Yield | 5.19% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 55.57% |
| Buyback Yield | -2.61% |
| Shareholder Yield | 2.58% |
| Earnings Yield | 9.37% |
| FCF Yield | 12.47% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 9, 2018. It was a forward split with a ratio of 1.1.
| Last Split Date | Jul 9, 2018 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
Syngen Biotech has an Altman Z-Score of 4.39 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.39 |
| Piotroski F-Score | 6 |